CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aptose Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aptose Biosciences Inc
251 Consumers Rd Suite 1105
Phone: (647) 479-9828p:647 479-9828 NORTH YORK, ON  M2J 4R3  Canada Ticker: APTOAPTO

Business Summary
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer William G.Rice 64 4/7/2022 10/28/2013
Chief Financial Officer, Senior Vice President FletcherPayne 60 6/27/2022 6/27/2022
Senior Vice President, Chief Medical Officer RafaelBejar 52 1/1/2020 1/1/2020
6 additional Officers and Directors records available in full report.

Business Names
Business Name
APTO
Aptose Biosciences U.S. Inc.
Lorus Therapeutics Inc.
Lorus Therapeutics Inc. (USA)
Nuchem Pharmaceuticals Inc.

General Information
Number of Employees: 35 (As of 12/31/2022)
Outstanding Shares: 6,519,201 (As of 8/10/2023)
Shareholders: 38
Stock Exchange: NASD
Fax Number: (416) 798-2200
Email Address: INFO@LORUSTHERA.COM


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023